The9 Investee Nanyang Biologics (Nyb) Advancing Planned Nasdaq Listing For The $1.5 Billion Business Combination - NCTY News | RalliesThe9 Investee Nanyang Biologics (Nyb) Advancing Planned Nasdaq Listing For The $1.5 Billion Business Combination
N
NCTY• The9 investee advancing Nasdaq listing plan
- The9 Ltd said its investee Nanyang Biologics (NYB) is advancing a planned Nasdaq listing through a US$1.5 billion business combination.
- The9 expects to own 15% to 16% of the combined company after the NYB listing.
- The Nasdaq listing is subject to a SPAC meeting on Aug. 19, 2026 and Nasdaq approval.
NESR
•
